Diagnostic tools company Prescient Medicine Holdings Inc disclosed on Tuesday the completion of the acquisition of AutoGenomics Inc for an undisclosed amount.
Based in the US, AutoGenomics Inc is a molecular diagnostics company that has developed and commercialised the INFINITI platform, a 510(k) exempt, automated, microarray-based multiplexing diagnostic system for personalised medicine, pain management, cardiovascular health, mental health, women's health, oncology, infectious diseases and genetic disorders.
Following the acquisition of AutoGenomics, Prescient Medicine will now advance the development and commercialisation of the INFINITI Neural Response Panel, a novel diagnostic test for the identification of patients who may be at risk for opioid use disorder (OUD), through the US FDA's de Novo premarket submission.
In conjunction with the acquisition, Prescient Medicine will market the INFINITI Neural Response Panel as LifeKit Predict to provide physicians with objective information to help assess the risk of developing an addiction to oral opioids.
The acquisition provides Prescient Medicine with access to the entire INFINITI product portfolio including the suite of INFINITI analyzers and a menu of over 65 molecular diagnostic tests across critical disease indications, which will complement Prescient Medicine's LifeKit product line of diagnostics.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886